{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang H"],"funding":["Natural Science Foundation of Beijing Municipality","National Natural Science Foundation of China","Foundation for Innovative Research Groups of the National Natural Science Foundation of China","National High-tech Research and Development Program","Beijing Natural Science Foundation"],"pagination":["111018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11490723"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(10)"],"pubmed_abstract":["Heart failure (HF) is a global concern, particularly HF with preserved ejection fraction (HFpEF), lacking effective treatments. Understanding the differences of metabolic profiles between HFpEF and HFrEF (heart failure with reduced ejection fraction) patients is crucial for therapeutic advancements. In this study, pseudotargeted metabolomics was employed to analyze for disparities of plasma metabolic profiles between HFpEF and HFrEF in two cohorts: discovery (<i>n</i> = 514) and validation (<i>n</i> = 3368). Plasma-free carnitine levels were significant changed in HF patients. A non-linear and U-shaped (for HFpEF) or J-shaped (for HFrEF) association between circulating free carnitine levels and the composite risk of cardiac events were observed. Interestingly, HFpEF patients with low free "],"journal":["iScience"],"pubmed_title":["Carnitine is a friend in HFpEF and foe in HFrEF."],"pmcid":["PMC11490723"],"funding_grant_id":["J230039","7242163","82104159","2023YFA1800904","NO.L232031","L232031","2020YFA0803700","NO.J230039"],"pubmed_authors":["Wu J","Zhu Y","Guo Y","Ji L","Liu Q","Pan B","Wang H","Yao X","Zhang Q","Shan W","Li X","Wang DW","Zhao M","Zhan R","Zheng L","Cui H","Wei H","Fang L","Fei M","Wu Y","Lin N"],"additional_accession":[]},"is_claimable":false,"name":"Carnitine is a friend in HFpEF and foe in HFrEF.","description":"Heart failure (HF) is a global concern, particularly HF with preserved ejection fraction (HFpEF), lacking effective treatments. Understanding the differences of metabolic profiles between HFpEF and HFrEF (heart failure with reduced ejection fraction) patients is crucial for therapeutic advancements. In this study, pseudotargeted metabolomics was employed to analyze for disparities of plasma metabolic profiles between HFpEF and HFrEF in two cohorts: discovery (<i>n</i> = 514) and validation (<i>n</i> = 3368). Plasma-free carnitine levels were significant changed in HF patients. A non-linear and U-shaped (for HFpEF) or J-shaped (for HFrEF) association between circulating free carnitine levels and the composite risk of cardiac events were observed. Interestingly, HFpEF patients with low free ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-02T22:23:14.08Z","creation":"2025-04-06T14:23:48.926Z"},"accession":"S-EPMC11490723","cross_references":{"pubmed":["39429785"],"doi":["10.1016/j.isci.2024.111018"]}}